Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Mabwell (Shanghai) Bioscience Co., Ltd.
No Price
Closing Price XSHG 30.04.2026:
35,73 CNY
30.04.2026 07:00
Current Prices from Mabwell (Shanghai) Bioscience Co., Ltd.
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
SSE
688062.SS
CNY
30.04.2026 07:00
35,73 CNY
-
Share Float & Liquidity
Free Float78,24 %
Shares Float312,64 M
Shares Outstanding399,6 M
Company Profile for Mabwell (Shanghai) Bioscience Co., Ltd. Share
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of biological products in China and internationally. The company offers its products for auto-immune, oncology, ophthalmologic, and infectious diseases, as well as metabolic disorders, etc. It offers JUNMAIKANG, an autoimmune Adalimumab injection. The company’s oncology products pipeline includes 9MW2821 and 6MW3211, which are in phase II of clinical trial; 9MW2921, 9MW3811, and 7MW3711, which are in phase I clinical trials; 9MW0321; and 8MW0511, which is in phase III clinical trial. It also develops autoimmune products, such as 9MW1911 and 9MW3811, which are in phase 1 clinical trial; metabolic products comprising MAILISHU and 9MW3011; ophthalmology candidates, including 9MW0813 and 9MW0211 that are in phase III clinical trial; and 9MW1411, an infectious product candidate. The company was founded in 2017 and is based in Shanghai, China.
